# A Study of Ziprasidone for the Treatment of Psychosis in Patients Who Had Already Had Benefits From Ziprasidone Treatment in a Previous Study

> **NCT00645320** · PHASE4 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 75 (actual)

## Conditions studied

- Pyschotic Disorders

## Interventions

- **DRUG:** Ziprasidone

## Key facts

- **NCT ID:** NCT00645320
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** —
- **Final completion:** 2004-08
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2021-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00645320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00645320, "A Study of Ziprasidone for the Treatment of Psychosis in Patients Who Had Already Had Benefits From Ziprasidone Treatment in a Previous Study". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00645320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*